Do not share your Ozempic® pen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.
Covered products:
Wegovy® (semaglutide) injection 2.4 mg
Total strength per total volume
NDC
0.25 mg/0.5 mL
0169-4525-14
0.5 mg/0.5 mL
0169-4505-14
1 mg/0.5 mL
0169-4501-14
1.7 mg/0.75 mL
0169-4517-14
2.4 mg/0.75 mL
0169-4524-14
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, 2 mg
Total strength per total volume
NDC
2 mg/3 mL
0169-4181-13
4 mg/3 mL
0169-4130-13
8 mg/3 mL
0169-4772-12
Eligibility and Restrictions
Ozempic®:
To participate in the Ozempic® NovoCare® Pharmacy program, patients must have a valid prescription for Ozempic®. A valid Prescriber ID# is required on the prescription.
Patients are not eligible for the Ozempic® NovoCare® Pharmacy program if enrolled in any federal or state health care program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a government program), or where prohibited by law.
Patients may only participate in this NovoCare® program for Ozempic® if they have been prescribed Ozempic® for an FDA-approved indication within that product’s labeling.
Wegovy®:
In order to participate in the Wegovy® NovoCare® Pharmacy program, patient must have a valid prescription for Wegovy®. A valid Prescriber ID# is required on the prescription.
Patients must either be uninsured or have insurance but decide to self-pay. Patients may only participate in this Wegovy® program if they have been prescribed Wegovy® for an FDA-approved indication with that product’s labeling.
Program Details for Ozempic®
By using this program, patient must certify that they meet the eligibility criteria and will comply with the terms and conditions described for Ozempic® Eligibility, Ozempic®’s Program Details, and Program Details applicable to either Ozempic® or Wegovy®.
Patient agrees they will not seek reimbursement for any medication received through this program.
When a prescription for Ozempic® is received from a licensed prescriber, NovoCare® will review and validate the prescription. Patients will have the option to utilize the self-pay/cash program through CenterWell® and/or CoAssist Pharmacy d/b/a NovoCare® Pharmacy (“NovoCare® Pharmacy”), or for those who have commercial insurance, have NovoCare® Pharmacy transfer the prescription to a retail pharmacy to apply their commercial prescription insurance to the prescription fulfillment.
Program Details for Wegovy®
By using this program, patient must certify that they meet the eligibility criteria and will comply with the terms and conditions described for Wegovy® Eligibility, Wegovy®’s Program Details, and Program Details applicable to either Wegovy® or Ozempic®.
Patient also agrees that they will not seek reimbursement for any medication received through this program.
When a prescription for Wegovy® is received from a licensed prescriber, NovoCare® will review and validate the prescription. Patients will have the option to utilize the self-pay/cash program through CenterWell® and/or CoAssist Pharmacy d/b/a NovoCare® Pharmacy (“NovoCare® Pharmacy”).
Patients in this Wegovy® self-pay program who otherwise might participate in Medicare Part D or a Medicare Advantage prescription drug plan must agree to the following conditions for the Wegovy® self-pay/NovoCare® Pharmacy program:
Program Details that Apply to Wegovy® or Ozempic®
NovoCare® Pharmacy operates through licensed pharmacies that dispense product under a cash-pay model, and insurance is not accepted. These cash prescriptions are filled by CenterWell® Pharmacy or CoAssist Pharmacy d/b/a Novocare® Pharmacy.
Patients enrolled in this program can pay $499 per 28-day supply (1 box), $998 per 56-day supply (2 boxes), or $1,497 per 84-day supply (3 boxes) of Wegovy® or Ozempic®, as submitted by the prescriber. Patients must provide payment prior to the dispensing and shipment of their prescription.
Novo Nordisk’s Eligibility and Restrictions, and Program Details, may change from time to time, and for the most recent version, please visit this webpage. Reconfirmation of patient information may be requested periodically to ensure accuracy of data and compliance with terms. Patients with questions about the program may call 1-888-809-3942.
This offer is not insurance. This offer is not contingent on any past, current, or future purchase of Ozempic® or Wegovy®. This offer cannot be combined with any other coupon, free trial, discount, prescription savings card, or other offer not associated with this offer. This offer is valid only in the United States and its territories, unless prohibited by law.
Assurance of Medication Supply
This program will continue to enroll patients so long as each enrolled patient can receive a consistent supply of medication. This assurance is only applicable for those patients who remain enrolled and adherent to the treatment. Novo Nordisk reserves the right to pause or terminate enrollment to prioritize supply for those qualified.
Disclosure of Third-Party Partnerships
AssistRx: A patient solutions provider responsible for NovoCare®’s access and reimbursement live support program. They manage patient intake and outreach and offer live support.
CoAssist: A licensed pharmacy in all 50 US States and territories that for purposes of this program is CoAssist Pharmacy d/b/a NovoCare® Pharmacy. CoAssist takes in the prescription after NovoCare®’s access and reimbursement live support program reviews patient’s insurance type and benefits investigation to determine eligibility for program. Eligible patients may then have their HCP’s prescription transferred from CoAssist to CenterWell® Pharmacy, where CenterWell® further validates the prescription, and processes it for shipment to patient’s home or CoAssist Pharmacy d/b/a NovoCare® Pharmacy may act as the dispensing pharmacy.
CenterWell®: NovoCare®’s dispensing pharmacy responsible for patient accounts, payment collection, medication fulfillment, tracking, and shipping.